WO2013105997A3 - Compositions et procédés de remplacement de tissu mou améliorés - Google Patents

Compositions et procédés de remplacement de tissu mou améliorés Download PDF

Info

Publication number
WO2013105997A3
WO2013105997A3 PCT/US2012/025400 US2012025400W WO2013105997A3 WO 2013105997 A3 WO2013105997 A3 WO 2013105997A3 US 2012025400 W US2012025400 W US 2012025400W WO 2013105997 A3 WO2013105997 A3 WO 2013105997A3
Authority
WO
WIPO (PCT)
Prior art keywords
soft tissue
compositions
tissue replacement
replacement methods
improved soft
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/025400
Other languages
English (en)
Other versions
WO2013105997A2 (fr
Inventor
Dennis E. Van Epps
Guang-Liang Jiang
Adam L. Collette
Rebecca L. Horan
Jing-song CHEN
Gregory H. Altman
Wha-Bin Im
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/193,744 external-priority patent/US8697056B2/en
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to EP12708197.4A priority Critical patent/EP2678022A2/fr
Publication of WO2013105997A2 publication Critical patent/WO2013105997A2/fr
Anticipated expiration legal-status Critical
Publication of WO2013105997A3 publication Critical patent/WO2013105997A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Insects & Arthropods (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne des compositions et des procédés permettant de traiter un défaut de tissu mou chez un individu.
PCT/US2012/025400 2011-02-23 2012-02-16 Compositions et procédés de remplacement de tissu mou améliorés Ceased WO2013105997A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12708197.4A EP2678022A2 (fr) 2011-02-23 2012-02-16 Compositions et procédés de remplacement de tissu mou améliorés

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161445928P 2011-02-23 2011-02-23
US61/445,928 2011-02-23
US13/193,744 2011-07-29
US13/193,744 US8697056B2 (en) 2010-08-19 2011-07-29 Compositions and soft tissue replacement methods

Publications (2)

Publication Number Publication Date
WO2013105997A2 WO2013105997A2 (fr) 2013-07-18
WO2013105997A3 true WO2013105997A3 (fr) 2014-01-09

Family

ID=48782054

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/025400 Ceased WO2013105997A2 (fr) 2011-02-23 2012-02-16 Compositions et procédés de remplacement de tissu mou améliorés

Country Status (2)

Country Link
EP (1) EP2678022A2 (fr)
WO (1) WO2013105997A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060069018A1 (en) * 2002-10-10 2006-03-30 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
US20110008406A1 (en) * 2009-04-20 2011-01-13 Altman Gregory H Silk Fibroin Hydrogels and Uses Thereof
US20110009960A1 (en) * 2001-11-16 2011-01-13 Allergan, Inc. Prosthetic fabric structure
WO2012024072A1 (fr) * 2010-08-19 2012-02-23 Allergan, Inc. Compositions à base de tissu adipeux et d'un analogue de la pge2 et leur utilisation dans le traitement d'une affection d'un tissu mou

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4756911A (en) 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6110590A (en) 1998-04-15 2000-08-29 The University Of Akron Synthetically spun silk nanofibers and a process for making the same
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US20080299213A2 (en) 1999-11-05 2008-12-04 Donald Kleinsek Augmentation and repair of spincter defects with cells including adipocytic cells
US6673285B2 (en) 2000-05-12 2004-01-06 The Regents Of The University Of Michigan Reverse fabrication of porous materials
US6423252B1 (en) 2000-06-23 2002-07-23 Ethicon, Inc. Methods of making micropatterned foams
EA200300379A1 (ru) 2000-11-27 2003-08-28 Пфайзер Продактс Инк. Селективные агонисты рецептора ep4 в лечении остеопороза
IL159996A0 (en) 2001-07-23 2004-06-20 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
US6902932B2 (en) 2001-11-16 2005-06-07 Tissue Regeneration, Inc. Helically organized silk fibroin fiber bundles for matrices in tissue engineering
US20040254230A1 (en) 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US7651684B2 (en) 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
AU2003253690A1 (en) 2002-06-24 2004-01-06 Massachusetts Institute Of Technology Silk biomaterials and methods of use thereof
CA2525994C (fr) 2002-06-24 2012-10-16 Tufts University Biomateriaux a base de soie et leurs methodes d'utilisation
WO2004062697A2 (fr) 2003-01-07 2004-07-29 Tufts University Matières de fibroïne de soie et utilisation de celles-ci
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
US6875787B2 (en) 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
CA2562415C (fr) 2003-04-10 2015-10-27 Tufts University Solution aqueuse concentree de fibroine
EP1670385B1 (fr) 2003-10-01 2013-01-23 University of Washington Nouveaux biomateriaux poreux
CA2553381C (fr) 2004-01-20 2011-03-22 Allergan, Inc. Compositions pour traitement local de l'oeil, comprenant de preference de l'acetonide de triamcinolone et de l'acide hyaluronique
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
EP1782829A1 (fr) 2004-08-10 2007-05-09 Ono Pharmaceutical Co., Ltd. Prévention et/ou remède pour hyperpotassémie contenant un agoniste ep4
JP4985400B2 (ja) 2005-06-24 2012-07-25 大正製薬株式会社 プロスタグランジン誘導体
US20070036844A1 (en) 2005-08-01 2007-02-15 Ma Peter X Porous materials having multi-size geometries
FR2896511B1 (fr) 2006-01-26 2012-10-26 Centre Nat Rech Scient Procede de culture de cellules issues du tissu adipeux et leurs applications.
WO2008092861A1 (fr) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Dérivés bicycliques utilisés comme agonistes de ep4
WO2008092862A1 (fr) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Dérivés bicycliques utilisés comme agonistes de ep4
WO2008092860A1 (fr) 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Dérivés bicycliques comme agonistes de ep4
US20090317367A1 (en) 2007-02-21 2009-12-24 Cedars-Sinai Medical Center Methods of producing preadipocytes and increasing the proliferation of adult adipose stem/progenitor cells
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
GB0810615D0 (en) 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009960A1 (en) * 2001-11-16 2011-01-13 Allergan, Inc. Prosthetic fabric structure
US20060069018A1 (en) * 2002-10-10 2006-03-30 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
US20110008406A1 (en) * 2009-04-20 2011-01-13 Altman Gregory H Silk Fibroin Hydrogels and Uses Thereof
WO2012024072A1 (fr) * 2010-08-19 2012-02-23 Allergan, Inc. Compositions à base de tissu adipeux et d'un analogue de la pge2 et leur utilisation dans le traitement d'une affection d'un tissu mou

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALTMAN A M ET AL: "Adhesion, migration and mechanics of human adipose-tissue-derived stem cells on silk fibroinchitosan matrix", ACTA BIOMATERIALIA, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 4, 1 April 2010 (2010-04-01), pages 1388 - 1397, XP026921459, ISSN: 1742-7061, [retrieved on 20091025], DOI: 10.1016/J.ACTBIO.2009.10.034 *

Also Published As

Publication number Publication date
EP2678022A2 (fr) 2014-01-01
WO2013105997A2 (fr) 2013-07-18

Similar Documents

Publication Publication Date Title
EP3285688A4 (fr) Implants cornéens
EP2667787A1 (fr) Réparation tissulaire
WO2012149472A9 (fr) Procédés, compositions et trousses pour traiter et prévenir des états neurologiques
EP2531138A4 (fr) Implants intraoculaires, et kits et procédés associés
EP2663653A2 (fr) Méthodes de diagnostic et de traitement de troubles liés à la longueur de l' il
EP2663258A2 (fr) Prothèse valvulaire destinée à remplacer une valvule auriculo-ventriculaire du coeur
EP2739237A4 (fr) Instrument chirurgical et son procédé de commande
EP2667813A1 (fr) Procédé de planification du positionnement d'un implant
EP2757999A4 (fr) Implant de tissu dur
GB201305198D0 (en) Kits, components and methods for tissue reconstruction
PT2689743T (pt) Broca para cirurgia de implantes
BR112014004192A2 (pt) composição de tratamento de sementes, e, método de tratamento de sementes
WO2013023151A3 (fr) Compositions et méthodes de traitement de maladie cœliaque
PT2681280T (pt) Biomaterial, método para preparar o biomaterial e utilizações do mesmo
EP2565618A3 (fr) Testeur de dureté
EP2903537A4 (fr) Suture pour réparation de tissu mou
GB2505800B (en) Valve body arrangement and method for manufacture thereof as well as valve having the valve body arrangement
WO2012097272A8 (fr) Compositions d'hydrogel stable incluant des additifs
WO2013038269A3 (fr) Appareil et procédés permettant de traiter des morceaux de tiges de canne à sucre
EP2732068B8 (fr) Procédé pour améliorer la résistance à l'usure d'instruments chirurgicaux colorés
EP3016516A4 (fr) Greffon formé de tissus mous
WO2012112757A3 (fr) Compositions et procédés améliorés de remplacement de tissu mou
WO2011097577A9 (fr) Compositions et procédés pour traiter ou prévenir une dégénérescence de la rétine
WO2012078746A9 (fr) Compositions et procédés pour la mobilisation de cellules souches
WO2013105997A3 (fr) Compositions et procédés de remplacement de tissu mou améliorés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12708197

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2012708197

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012708197

Country of ref document: EP